Pharmacokinetic Comparison and Bioequivalence Evaluation between a Newly Formulated Generic and the Brand Cefuroxime Axetil Tablets in Healthy Male Adult Fasting Subjects
-
Published:2022-05-30
Issue:
Volume:
Page:2184-2192
-
ISSN:0974-360X
-
Container-title:Research Journal of Pharmacy and Technology
-
language:en
-
Short-container-title:RJPT
Author:
Jaber Al-Tamimi Duaa Jaafar1, Abbas Al-Mahroos Mustafa Ihssan2, Jaber Al-Tamimi Mariam Jaafar3, Jaber Ibraheem Jaafar3
Affiliation:
1. Department of Pharmacy, Al-Nisour University College, Ministry of Higher Education and Scientific Research, Baghdad, Iraq. 2. College of Pharmacy, Alfarahidi University, Ministry of Higher Education and Scientific Research, Baghdad, Iraq. 3. Department of Pharmacy, Al-Manara College for Medical Sciences, Ministry of Higher Education and Scientific Research, Missan, Amarah, Iraq.
Abstract
Cefuroxime axetil (CA) is a broad-spectrum second-generation cephalosporin antibiotic resistant to beta-lactamase used for treating different kinds of infections. This study was conducted to compare the pharmacokinetics (PK) and to evaluate the bioequivalence (BE) between a newly formulated generic CA 500mg tablets as a test formula with the same dose of the brand formula as the reference product applying 2-way, 2-treatment, 2-period, 2-sequence, randomized crossover design with six days washout interval between dosing. After overnight fasting for 12 hours, both CA products were administered to 28 healthy male adult Arabic subjects, followed by serial blood samples obtained from each subject before drug dosing (0-hr) and then up to 8 hours post-dosing. The calculated PK parameters Cmax, Tmax, AUC0–t, AUC0–∞, Thalf, MRT, Cl and Vd obtained from each product were statistically compared by ANOVA and 90% confidence interval tests to evaluate the BE between both products. Based on international guidance on bioequivalences like FDA and EMEA, it was concluded from this research that the test and the reference formulas are bioequivalent since the 90% confidence intervals were within the accepted ranges of 80.00-125.00%. All participants tolerated both products well, and they were discharged without any significant alterations in their clinical baseline characteristics. Therefore, the newly formulated generic CA 500mg tablets may be prescribed in clinical practice and used as a safe and effective alternative to the brand product.
Publisher
A and V Publications
Subject
Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference53 articles.
1. PrCeftin product monograph, GlaxoSmithKline Inc., 7333 Mississauga Road, Mississauga, Ontario, L5N 6L4, Control Number: 234485, Date of Revision: May 5, 2020. 2. Zinnat product information, GlaxoSmithKline, 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK, Date of revision of the text: November 2019. 3. Sara T , Klaus SJ , Ninna BN, Martin S , Dennis SH , Kai HWL , et al . Cefuroxime pharmacokinetics and pharmacodynamics for intravenous dosage regimens with 750 mg or 1500 mg doses in healthy young volunteers. J Med Microbiol. 2020;69(3):387-395. 4. Iyad NM, Muhammad HS, Rabia IY, Muhammad H, Sabahat J, Tariq A. Formulation Development and Optimization of Cefuroxime Axetil tablets by Direct Compression Method and its Stability Studies. Lat Am J Pharm. 2012;31(2):271-278. 5. Fozia I , Zafar AM , Fouzia H, Syed MFH, Sabahat J, Shazia N, et al. Formulation design and evaluation of Cefuroxime axetil 125 mg immediate release tablets using different concentration of sodium lauryl sulphate as solubility enhancer. Brazi J of Pharm Sci. 2014;50(4):943-953.
|
|